

A Survey on the Role of Interleukin-10 in Breast Cancer: A Narrative

Elnaz Sheikhpour¹, Parisa Noorbakhsh^{*2}, Elnaz Foroughi³,
Soudabeh Farahnak⁴, Rezvan Nasiri⁵, Hossein Neamatzadeh⁶

Abstract

Interleukin (IL)-10, a multifunctional immune-regulatory cytokine with both immunosuppressive and anti-angiogenic functions, is produced by immune cells including macrophages, T lymphocytes, and natural killer cells. Among other effects, IL-10 promotes tumor cell proliferation and metastasis via immunosuppression. Interleukin-10-mediated immunosuppression is aided by synthesis of tumor necrosis factor, IL-1, IL-12, and chemokines, and down regulation of the surface co-stimulatory molecules CD80 and CD86 on tumors. Interleukin-10 also promotes IL-6 expression and synthesis, which causes cell proliferation via B cell lymphoma-2 (Bcl-2) upregulation and changes the proliferation/apoptosis equivalence toward neoplastic cell proliferation. Moreover, IL-10 inhibits tumorigenesis via down-regulation of VEGF, IL-1b, TNF- α , IL-6, and MMP-9. Interleukin-10 also inhibits nuclear factor- κ B (NF- κ B) translocation. Interleukin-10 has been reported to have both tumor-promoting and -inhibiting properties. It seems that IL-10 agonists and antagonists may have therapeutic effects via different mechanisms. Moreover, IL-10 gene polymorphisms may determine breast cancer susceptibility.

Keywords: Breast cancer, Cytokine, IL-10

Introduction

Breast cancer is the most common cancer in women (1, 2), accounting for 25% of all female cancers worldwide (3). Despite new diagnostic and treatment options (3), 30% of women diagnosed with invasive breast cancer will develop metastatic disease (4); therefore, early detection is critical for patient survival. Immunoregulatory cytokines including interferons-(IFNs) - α , - β , and - γ ; interleukins-(ILs) -2, -6, and -10, and tumor necrosis factor (TNF) - α are all associated with breast cancer (3, 5, 6, 7). Interleukin-10, which has an important coordinated role in breast carcinogenesis (3), is an anti-inflammatory cytokine that regulates the immune response (8) and inhibits the pro-inflammatory functions

of antigen-presenting cells (APCs) through expression of antagonizing costimulatory molecules. Its low expression is associated with poor survival outcome (9). The aim of this study is to evaluate the mechanism and action of IL-10 in breast cancer patients.

Interleukin-10 (IL-10)

The IL-10 gene (*IL10*) contains five exons (10) located on chromosome 1 at q31-32 (11). The protein contains 160 amino acids, has a molecular weight of 18 kDa, and functions as a dimer (5). Human IL-10 is 73% homologous with murine IL-10 at the amino acid level (5) and is produced by

1: Hematology and Oncology Research Center, Shahid Sadoughi University of Medical Science, Yazd, Iran.

2: Department of Immunology, School of Medicine, Arak university of Medical Sciences, Arak, Iran.

3: Department of Pediatric Dentistry, Arak university of Medical Sciences, Arak, Iran.

4: Department of Endodontic, Arak university of Medical Sciences, Arak, Iran.

5: Department of Restorative and Esthetic, Arak University of Medical Sciences, Arak, Iran.

6: Mother and Newborn Health Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

*Corresponding authors: Parisa Noorbakhsh; Tel: +98 9131522462; Fax: +98 35 36235958; E-mail: parisanourbakhsh@yahoo.com.

Received: Apr 18, 2017; Accepted: Jul 22, 2017

immune cells including macrophages, T lymphocytes, and natural killer (NK) cells (12). It is a multifunctional immuno-regulatory cytokine (13) with both immunosuppressive (14, 15) and anti-angiogenic functions (14). It also plays major roles in the regulation of inflammatory responses, infection progression, autoimmunity, transplantation tolerance, and tumorigenesis (16, 17). Also known as cytokine synthesis inhibitory factor (CSIF), IL-10 suppresses expression of ILs-1 α , -1 β , -6, -8, -12, and -18, TNF- α , and granulocyte-macrophage colony-stimulating factor (GM-CSF) in T cells and macrophages (5), IFN- γ in activated T helper (Th) cells and peripheral blood mononuclear cells (PBMCs), and induces mast cell proliferation. Interleukin-10 deficiency is associated with increased production of the pro-inflammatory cytokine IL-1, which promotes tumor growth in mice (8).

IL-10 and alpha-2-Macroglobulin (α 2M)

Interleukin-10 has many functional partners including alpha-2-macroglobulin (α 2M) (18), with which it can form a complex. Alpha-2-macroglobulin, a large homotetrameric glycoprotein (19) found in plasma and extracellular spaces, acts a protease inhibitor and can non-covalently bind (20) and transport cytokines, including IL-10. The formation of these complexes increases the concentrations of these cytokines in the

blood (21, 22). Native α 2M increases the half-life of bound cytokines in the plasma by protecting them from proteolysis (20) and facilitates their recruitment to inflammation sites, where they induce anti-inflammatory responses (22, 23). Disruption of these complexes promotes inflammation (21, 22) and favors cancer development.

IL-10 Polymorphism

Genetic polymorphism can play a role in initiation and progression of breast cancer (5). Genetic variations that affected IL-10 synthesis determined breast cancer susceptibility (11). Several single-nucleotide polymorphisms (SNPs) have been identified in the *IL10* promoter (10). Three functional *IL10* SNPs have been characterized; these are an adenine (A) to guanine (G) substitution at nucleotide -1082 (rs1800896), a thymine (T) to cytosine (C) substitution at nucleotide -819 (rs1800871), and an A to C substitution at nucleotide -592 (rs1800872). These polymorphisms led to different *IL10* expression levels and determined inter-individual differences in IL-10 (3). Moreover, factors including study population ethnicity, sample size, and subject inclusion and exclusion criteria affected findings (5). *IL10* polymorphisms and their associations with breast cancer are shown in Table 1.

Table 1. *IL10* polymorphisms associated with breast cancer

Study	Polymorphism	Population	Result	References
Giordani et al. (2003)	-1082	Italy	The -1082 polymorphism was associated with cancer risk	42
Abdolrahim-Zadeh et al. (2005)	-1082 -819 -592	Iran	No association was found between these polymorphisms and breast cancer	11
Langsenlehner et al. (2005)	-592	Austria	Association between The -592 polymorphism was associated with decreased breast cancer risk	25
Gerger et al. (2010)	-592	Austria	The -592 polymorphism was associated with breast cancer metastasis	15
Merendino et al. (1999)	-1082 -592	Brazil	No association was found between genotypes or haplotypes and sporadic breast cancer	26
Smith et al. (2004)	-1082	UK	No association was found between the -1082 A/G polymorphism and breast cancer susceptibility	27

IL-10 Induction and inhibition factors

Several factors influence IL-10 induction and inhibition. These agents are shown in Table 2.

Table 2. IL-10 inducing and inhibiting agents

Investigator	Agent	Effect	References
Pilette et al. (2007)	Immunoglobulin-A (Iga)	Inducing	28
McGeachy et al. (2007)	Transforming Growth Factor-B (TGF-B)	Inducing	29
McGeachy et al. (2007)	Interleukin-6 (IL-6)	Inducing	29
Awasthi A, et al. (2007)	Interleukin-27 (IL-27)	Inducing	30
Pang G et al. (1994)	Interleukin-1 α (IL-1-A)	Weakly Inducing	31
Pang G et al. (1994)	Tumor Necrosis Factor-A (TNF-A)	Weakly Inducing	31
Scott et al. (1990)	Lipopolysaccharide (LPS)	Inducing	32
Brunsing et al. (2011)	G Protein-Coupled Estrogen Receptor (GPER) Agonist	Inducing	33
Brunsing et al. (2011)	Thalidomide	Inducing	33
Ji et al. (2005)	15-Deoxy-Delta12,14-Prostaglandin J2	Inhibiting	34
Kalechman et al. (2004)	AS101 (Ammonium Trichloro (Dioxoethylene-O,O') Tellurate)	Inhibiting	35
Alas et al. (2001)	Rituximab	Inhibiting	36

IL-10 signaling pathways and chemotherapy

Interleukin-10 signals through a tetrameric trans-membrane receptor complex containing two IL-10RA (also known as IL-10R1) and two IL-10RB (also known as IL-10R2) proteins (8). Both receptors belong to the class II receptor family containing one each of intracellular, trans-membrane, and extracellular domains (8). These receptor complexes assemble consecutively; IL-10RA has greater affinity for IL-10 than IL-10RB. Interleukin-10 binding to the IL-10RA extracellular domain leads to Janus kinase-1 (JAK1) and tyrosine kinase-2 (TYK2) phosphorylation.

Janus kinase-1 phosphorylates signal transducer and activator of transcription-3 (STAT-3). Once phosphorylated, STAT-3 translocate to the nucleus and activates transcription of anti-apoptotic and cell-cycle-progression genes (8). Moreover, IL-10 expression is regulated through a balance of STAT-3 and suppressor of cytokine signaling-3 (SOCS3); STAT-3 silencing decreased IL-10 expression (5). Recent studies showed N-Myc downstream regulated gene 2 product (NDRG2) modulates SOCS3 and STAT-3 activities and inhibits IL-10 production (5).

The relatively large amount of IL-10 secreted by tumor-associated macrophages (TAMs) was found to be responsible for breast cancer drug resistance.

The mechanism of TAMs-modulated drug resistance may be associated with increased *BCL2* expression and up-regulation of STAT3 signaling in tumor cells; therefore, the suppression of TAMs-induced IL-10 by neutralizing antibody leads to decreased *BCL2* expression and STAT3 activation and the consequent enhanced sensitivity of breast cancer cells to drug treatment. It seems that TAMs cause drug resistance via the IL-10/STAT3/Bcl-2 signaling pathway, providing possible new targets for breast tumor therapy (37). Tumor-associated macrophages can mediate with many tumor therapies including chemotherapy, irradiation, and immunotherapy (38). Chemotherapy-induced macrophage infiltration suppresses IL-12 synthesis in dendritic cells (DCs), which in turn inhibits CD8+ T cell activity and limits chemotherapy efficacy (38). Macrophages express the highest IL-10 levels among tumor infiltrating leukocytes, including T regulatory cells, known to be a main source of IL-10 in murine tumor models. Therefore, it seems likely that the IL-10/IL-10R and IL-12/IL-12R pathways

may play major roles in the pathological response following breast cancer chemotherapy-induced TAM recruitment. Moreover, targeting of these pathways may reduce chemotherapy resistance and improve patient outcomes (38).

IL-10 and apoptosis

An association exists between IL-10 expression and apoptosis-related tumor markers. A relationship between IL-10 and Bcl-2 has also been observed in human breast and other cancer cells (39). The effect of IL-10 on cell survival caused increased IL-6 expression, which promotes cell proliferation by upregulating *BCL2* expression, therefore changing the proliferation/apoptosis balance toward neoplastic cell proliferation (40). On the other hand, high IL-6 expression and its receptors in breast tumors may promote cell proliferation (40). Fernandez et al. showed IL-10 expression is strongly associated with expression of Bcl-2-associated X protein (Bax), a member of the Bcl-2 family with pro-apoptotic effects (39). Another study found no association between IL-10 and the apoptotic markers in breast tumors, but also reported that the presence of IL-10 and high abundance of Bcl-2 family proteins in tumors may show the aggressiveness of breast tumors (39). Kim et al. proposed a model for the role

of IL-10 in apoptosis of mammary epithelial cells; in this model IL-10 secreted through mammary epithelial cells recruit lymphocytes from blood vessels to the alveoli; then IL-10 stimulates lymphocytes to release the death factors Fas-L and TRAIL, which bind death factor receptors on epithelial cells. Then downstream signaling pathways activate epithelial cell apoptosis (41).

Relationship between IL-10 and breast cancer

The role of IL-10 in breast cancer is controversial. The results of various IL-10 studies in breast cancer are shown in Table 3.

Mechanism of IL-10 tumor act

The role of IL-10 in breast cancer is controversial. Interleukin -10 has both pro- and anti-tumor effects (50). IL-10 mRNA expression is seen in more than 50% of tumor samples (39). Also greater IL-10 protein concentrations are seen in serum of breast cancer patients than in that of healthy individuals (5, 39, 51) and this is associated with poor clinical outcomes (52). Interleukin-10 promoted proliferation and metastasis of tumor cells (53) and inhibited T-cell proliferation and function (39).

Therefore, it appears that IL-10 expression in metastatic cancer cells can down regulate the cell-

Table 3. Results of various studies on the role of IL-10 in breast cancer

Author	Result	Sample	References
Venetsanakos et al. (1997)	IL-10 mRNA detected in most breast tumors	Breast tumor tissue	42
Kozłowski et al. (2003)	Strong relationship between IL-10 expression and breast cancer	Serum breast cancer	43
Fernandez et al. (2006)	IL-10 is being a poor prognosticator for breast cancer	Breast tumor tissue	44
Chavey et al. (2007)	IL-10 protein expression was significantly greater in breast cancer tumors than in negative controls and inversely related to estrogen receptor- and progesterone receptor-status	Breast tumor tissue	45
Rao et al. (2008)	No significant difference in IL-10 expression was found between patients and controls	Serum of breast cancer	46
Li et al. (2014)	IL-10 expression is associated with disease-free survival.	Breast tumor tissue	47
Li, et al. (2014)	Low expression of IL-10 expression leads to poor survival outcome.	Breast tumor tissue	48
Venetsanakos. (1997)	IL-10 suppresses cellular immune responses	Breast tumor tissue	49

mediated inflammatory response (5) and be a potential biomarker for prediction and prognosis of human cancers (50). Interleukin -10 also mediates immunosuppression by upregulating TNF, ILs -1 and -12, and chemokine expression (54) and downregulating expression of surface co-stimulatory

molecules including CD80 and CD86 on tumor cells. It also prevents APCs from obtaining access to tumor antigens (54). It also appears that factors that contribute to IL-10 production may have potent roles in breast cancer development (11). Administration of IL-10 before anticancer

vaccination leads to tumor progression (55-58). Interleukin-10 stimulates metalloproteinase (TIMP) tissue inhibitors and inhibits expression of matrix metalloproteinase (MMP), thus affecting angiogenesis induction (10). Another study reported that IL-10 administration promoted proinflammatory effects through increased release of IFN- γ , IP-10, and other monokines induced by IFN- γ (59). Therefore, IL-10 antagonist administration may be an effective new cancer treatment (60).

Mechanism of IL-10 anti-tumor activity

Interleukin-10 expression is associated with anticancer immune responses in animal and human models. The anti-tumor activity of IL-10 is mediated via angiogenesis inhibition (11) and through down regulation of vascular endothelial growth factor(VEGF), ILs -1b and -6, TNF- α , and MMP-9 syntheses, all of which are needed for angiogenesis (54). It is also a potent stimulator of B-cell differentiation leading to immunoglobulin secretion. Interleukin-10 inhibits nuclear factor- κ B (NF- κ B) translocation as a mechanism to inhibit immediately pro-inflammatory responses (5). Therefore, IL-10 in the tumor site can prevent destruction by the host immune system (39) and suppress tumor growth and increase antitumor immunity via promotion of antitumor CTLs (55-58). The anti-tumor activity of IL-10 is also attributed to its effects on NK cell activation (10). Studies in animal models showed that IL-10 can activate NK cells and assist target cell destruction in a dose-dependent manner (59), while other research has indicated that the anti-tumor effect is due to CD8+ or CD4+ T-cell function (5). It seems that IL-10-mediated immune response inhibition at the tumor site has major

implications for immunotherapy (39). Therefore, IL-10 administration may be considered as a new therapy for cancer patients (59).

IL-10 and the estrogen receptor

The role of the estrogen receptor in cytokine production and regulation is not known (61). Interleukin-10 has been found in both tumor cell cytoplasm and stroma. Moreover, cytokines, including IL-10, were over-expressed in estrogen receptor (ER) -negative breast carcinoma (62). Because IL-10 was expressed in ER-negative but not ER-positive tumors (5), and expression of the transcription factor activator protein (AP) -1 is greater in ER-negative than in ER-positive tumors, the increased AP-1 expression is related to increased IL-10 (5). Therefore, IL-10 can be a breast cancer prognosticator (9). Moreover, G1, a G protein-coupled estrogen receptor (GPER) agonist, and Thalidomide can induce IL-10 expression by acting on Th17 or hybrid T-cell populations (5), while another study reported that increased IL-10 expression in tumor cell cytoplasm is associated with lower grade and positive estrogen receptor (9).

Conclusion

Interleukin-10 has been shown to exhibit both tumor-promoting and -inhibiting properties; therefore, it seems that IL-10 agonists and antagonists may have therapeutic effects in breast cancer via different mechanisms. Moreover, *IL10* polymorphisms may affect breast cancer susceptibility with lower grade and positive estrogen receptor (9).

Acknowledgement

We would like to thank Dr. Parichehr Yaghmaei for her assistance in writing of this paper.

References

1. Sheikhpour R. Evaluation of Tp53 codon 72 polymorphism and resulted protein in breast cancer patients in Yazd city. Iran J Breast Dis. 2014; 7 (3); 20-29.
2. Forat-Yazdi M, Rafieian S, Gholi-Nataj M, Sheikha MH, Nazari T, Neamatzadeh H. CYP2D6 genotype and risk of recurrence in tamoxifen treated breast cancer patients. Asian Pac J Cancer Prev. 2015;16(15):6783-7.
3. Sheikhpour R, Mohiti J. The effect of progesterone on p53 in T47D cell line. Urmia J Med Sci 2014; 25 (10), 954-960.
4. Sabe M, Nehs M, Gang S, Lowler S, Ferrara J, Chang A. Immunologic approaches to breast cancer treatment. Surg Oncol Clin N Am. 2005; 90(1): 97-104.
5. Khan H, Changkija B, Konwar R. Role of Interleukin-10 in Breast Cancer. Breast Cancer Res Treat. 2012; 133(1): 11-21.

6. Carpi A, Nicolini A, Antonelli A, Ferrari P, Rossi G. Cytokines in the management of high risk or advanced breast cancer: An update and Expectation. *Cur Cancer Drug Target*. 2009;9(8):888-903.
7. Konwar R, Chaudhary P, Kumar S, Mishra D, Chattopadhyay N, Bid HK. Breast cancer risk associated with polymorphisms of IL-1RN and IL-4 gene in Indian women. *Oncol Res*. 2009; 17(8):367-372.
8. Acuner-Ozbabacan ES, Hatice Engin B, Emine Guven-Maiorov E, Guray Kuzu G, Muratcioglu S, Alper Baspinar. The structural network of Interleukin-10 and its implications in inflammation and cancer. *BMC Genomics*. 2014; 15:S2-S5
9. Li Y, Yu H, Jiao S, Yang J. Prognostic value of IL-10 expression in tumor tissues of breast cancer patients. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*. 2014;30(5):517-20.
10. Howell MW. Interleukin-10 Gene Polymorphisms and Cancer. *Madame Curie Bioscience Database*. Landes Bioscience. 2000; 8:2013-2015.
11. Abdolrahim-Zadeh H, Hakkakian N, Asadollahi R, Gharesifard B, Sarvari J, Eskandar Kamali-Sarvestani E. Interleukin-10 Promoter Polymorphisms and Breast Cancer Risk in Iranian Women. *IJI*. 2005; 2(3):158- 165.
12. Sung W, Huei Lee H. The role of interleukin-10 in the progression of human papillomavirus-associated lung carcinoma. *Onco Immunol*. 2013; 2(9): 1-4.
13. Pooja S, Chaudhary P, Nayak LV, Rajender S, Singh Saini D. Polymorphic variations in IL-1b, IL-6 and IL-10 genes, their circulating serum levels and breast cancer risk in Indian women. *Cytokine*. 2012; 60: 122–128.
14. Fanjun Kong F, Jie Liu J. Association of interleukin-10 gene polymorphisms with breast cancer in a Chinese population. *J Exp Clin Canc Res*. 2010; 5: 9-15.
15. Gerger A, Renner W, Langsenlehner T, Hofmann G, Ketchell G, Szkandera J. Association of interleukin-10 gene variation with breast cancer prognosis. *Breast Cancer Res Treat*. 2010; 119:701–705.
16. Kim J, Modlin RL, Moy RL, Dubinett SM, McHugh T, Nickoloff BJ. IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. *J Immunol*. 1995;155:2240-7.
17. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consogno G. Increased interleukin-10 serum levels in patients with solid tumours. *Cancer Lett*. 1996;104:1-5.
18. Garber TR, Gonias SL, Webb DJ: Interleukin-4 and IL-10 bind covalently to activated human alpha2-macroglobulin by a mechanism that requires Cys949. *J Interferon Cytokine Res*. 2000, 20(2):125-131.
19. Sheikh AM, Chauhan V, Tsiouris JA, Mehta PD, Burguess K, Fenko MD, et al. Elevated levels of serum alpha (2) macroglobulin in wild black bears during hibernation. *Biochimie*. 2003, 85(10):1027-1032.
20. Zhevago NA, Samoilova KA: Pro- and anti-inflammatory cytokine content in human peripheral blood after its transcutaneous (in vivo) and direct (in vitro) irradiation with polychromatic visible and infrared light. *Photomed Laser Surg*. 2006; 24(2):129-139.
21. Borth W, Scheer B, Urbansky A, Luger TA, Sottrup-Jensen L. Binding of IL-1 beta to alpha-macroglobulins and release by thioredoxin. *J immunol*. 1990; 145(11):3747-3754.
22. Borth W: Alpha 2-macroglobulin. A multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. *Ann N Y Acad Sci*. 1994; 737:267-272.
23. Mosca R, Ceol A, Aloy P: Interactome3D: adding structural details to protein networks. *Nat Methods*. 2013, 10(1):47-53.
24. Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F. Association of breast cancer and polymorphisms of interleukin-10 and tumor necrosis factor-alpha genes. *Clin Chem*. 2003;49(10):1664-1667.
25. Langsenlehner U, Krippel P, Renner W, Yazdani-Biuki B, Eder T, Köppel H, et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. *Breast Cancer Res Treat*. 2005;90(2):113-115.
26. Merendino RA, Gangemi S, Misefari A, Arena A, Capozza AB, Chillemi S. Interleukin-12 and interleukin-10 production by mononuclear phagocytic cells from breast cancer patients. *Immunol Lett*. 1999; 68(2-3):355-358.

27. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. *Eur J Immunogenet.* 2004; 31:167-73.
28. Pilette C, Nouri-Aria KT, Jacobson MR, Wilcock LK, Detry B, Walker SM. Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression. *J Immunol.* 2007;178 (7):4658-4666.
29. McGeachy MJ, Bak-Jensen KS, Chen Y, Tato CM, Blumenschein W, McClanahan T. TGF-beta and IL-6 drive the production of IL-17 and IL-10 by T cells and restrain T(H)-17 cell mediated pathology. *Nat Immunol.* 2007;8 (12):1390-1397.
30. Awasthi A, Carrier Y, Peron JP, Bettelli E, Kamanaka M, Flavell RA. A dominant function for interleukin 27 in generating interleukin 10-producing anti-inflammatory T cells. *Nat Immunol.* 2007;8(12):1380-1389.
31. Pang G, Couch L, Batey R, Clancy R, Cripps A. GM-CSF, IL-1 alpha, IL-1 beta, IL-6, IL-8, IL-10, ICAM-1 and VCAM-1 gene expression and cytokine production in human duodenal fibroblasts stimulated with lipopolysaccharide, IL-1 alpha and TNF-alpha. *Clin Exp Immunol.* 1994; 96(3):437-443
32. Scott DE, Gause WC, Finkelman FD, Steinberg AD. Anti-CD3 antibody induces rapid expression of cytokine genes in vivo. *J Immunol.* 1990;145(7):2183-2188.
33. Brunsing RL, Prossnitz ER. Induction of interleukin-10 in the T helper type 17 effector population by the G protein coupled estrogen receptor (GPER) agonist G-1. *Immunology.* 2011; 134(1):93- 106.
34. Ji JD, Kim HJ, Rho YH, Choi SJ, Lee YH, Cheon HJ, Sohn J, Song GG. Inhibition of IL-10-induced STAT3 activation by 15-deoxy-Delta12,14-prostaglandin J2. *Rheumatology.* 2005; 44(8):983-988.
35. Kalechman Y, Gafter U, Weinstein T, Chagnac A, Freidkin I, Tobar A. Inhibition of interleukin-10 by the immunomodulator AS101 reduces mesangial cell proliferation in experimental mesangioproliferative glomerulonephritis: association with dephosphorylation of STAT3. *J Biol Chem.* 2004; 279(23):24724-24732.
36. Alas S, Emmanouilides C, Bonavida B. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. *Clin Cancer Res.* 2001;7(3):709-723.
37. Yang C, He L, He P, Liu Y, Wang W, He Y. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10/STAT3/bcl-2 signaling pathway. *Med Oncol.* 2015 ;32(2):352-355.
38. Jiang X. Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer. *Biomed Biotechnol.* 2015; 16(1):44-45.
39. Fernandez L, Alvarez-Goyanes R, Carmen Arango-Prado M, Alcocer-Gonzalez J. Relationship between IL-10 and tumor markers in breast cancer patients. *Breast.* 2006; 15: 482-489.
40. Garcia-tuñón I, Ricote m. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma. *histopathology.* 2005;47(1):82-9.
41. Kim T-W, Moon H-B, Jung Kim S. Interleukin-10 Is Up-regulated by Prolactin and Serum-Starvation in Cultured Mammary Epithelial Cells. *Mol Cell.* 2003; 16(2): 168-172.
42. Venetsanakos E, Beckman I, Bradley J, Skinner JM. High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. *Br J Cancer .* 1997;75(12):1826-1830.
43. Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. *Rocz Akad Med Białymst.* 2003; 48:82-84.
44. Llanes-Fernandez L, Alvarez-Goyanes RI, Arango-Prado Mdel C, Alcocer-Gonzalez JM, Mojarrieta JC, Perez XE. Relationship between IL-10 and tumor markers in breast cancer patients. *Breast.* 2006;15(4):482-489.
45. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinon S, Boissière F, Laune D. Oestrogen receptor negative breast cancers exhibit high cytokine content. *Breast Canc Res.* 2007; 9(1):R15-18
46. Rao VS, Alabi A, Dyer CE, Greenman J, Drew PJ. IL-10 and IL-12 expression in breast cancer patients and effect of therapy-ASCO Annual Meeting Proceedings (Post-Meeting Edition). *J Clin Oncol.* 2008; 26(15S): 14016-19.
47. Li Y, Gao P, Yang J, Yu H, Zhu Y, Si W. Relationship between IL-10 expression and prognosis in patients with primary breast cancer. *Tumour Biol.* 2014;35(11):11533-40.

48. Li Y, Yu H, Jiao S, Yang. Prognostic value of IL-10 expression in tumor tissues of breast cancer patients. *Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi*. 2014;30(5):517-20.
49. Venetsanakos E, Beckman I, Bradley J, Skinner J. High incidence of interleukin-10 mRNA but not interleukin-2 mRNA detected in human breast tumors. *Br J Cancer*. 1997;75: 1826–30.
50. Zhao S, Wu D, Wu P, Wang ZH, Huang J. Serum IL-10 Predicts Worse Outcome in Cancer Patients: A Meta-Analysis. *PLOS One*. 2015; 6: 1-15.
51. Kozłowski L, Zakrzewska I, Tokajuk P, Wojtukiewicz MZ. Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. *Rocz Akad Med Białymst*. 2003;48:82-4.
52. Visco C, Vassilakopoulos TP, Kliche KO, Nadali G, Viviani S, Bonfante V. Elevated serum levels of IL-10 are associated with inferior progression-free survival in patients with Hodgkin's disease treated with radiotherapy. *Leuk Lymphoma*. 2004; 45(10):2085–92.
53. Moore KW, De Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. *Annu Rev Immunol*. 2001; 19:683–765.
54. Vinod C, Jyothy A, Vijay kumar M, Raghu Raman R, Nallari P, Venkateshwari A. A common SNP of IL-10 (-1082A/G) is associated with increased risk of premenopausal breast cancer in south Indian women. *Iran J Cancer Prev*. 2015; 8(4):e3434-39.
55. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G. Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. *Clin Canc Res* 2004; 10(1): 7260-7271.
56. Groux H, Cottrez F, Rouleau M. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen presenting cells. *J Immunol* .1999;162:1723–9.
57. Berman RM, Suzuki T, Tahara H. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. *J Immunol*. 1996;157: 231–8.
58. Fujii S, Shimizu K, Shimizu T, Lotze MT. Interleukin-10 promotes the maintenance of antitumor CD8(-) T-cell effector function in situ. *Blood*. 2001;98:2143–51.
59. Mocellin S, Panelli MC, Wang E, D Nagorsen D, Marincola FM. The dual role of IL-10. *Trend Immunol*. 2003; 24(1): 36-44.
60. Mumm JB, Oft M. Pegylated IL-10 induces cancer immunity: the surprising role of IL-10 as a potent inducer of IFN-gamma-mediated CD8(+) T cell cytotoxicity. *Bio Essays*. 2013; 35(7):623–31.
61. Kassi E, Moutsatsou P. Estrogen Receptor Signaling and Its Relationship to Cytokines in Systemic Lupus Erythematosus. *J Biomed Biotechnol*. 2010; 8: 1-15.
62. Chavey C, Bibeau F, Gourgou-Bourgade S, Burlinchon S, BoissiÃ're F. Oestrogen Receptor Negative Breast Cancers Exhibit High Cytokine Content. *Breast Cancer Research*. *Breast Canc Res*. 2007;9(1): 5-10.